What is NDC 62756-218?

62756-218 is the product NDC for Ibandronate Sodium, Ibandronate sodium 3 mg/3mL injection, solution, listed with the FDA by Sun Pharmaceutical Industries, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Sun Pharmaceutical Industries, Inc., NDC labeler code 62756. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Ibandronate Sodium?

7 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Ibandronate Sodium NDC 62756-218 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)62756-218Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62756-0218Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62756-218-40	62756021840	1 VIAL, SINGLE-DOSE in 1 CARTON (62756-218-40) / 3 mL in 1 VIAL, SINGLE-DOSEMarketed from Feb 15, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ibandronate Sodium
Generic name (nonproprietary): ibandronate sodium
Active ingredients: Ibandronate sodium — 3 mg/3mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Sun Pharmaceutical Industries, Inc.NDC labeler code 62756
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090853
Marketing start: Feb 15, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 62756-218_61378ee8-cc2f-4f55-954b-4eb55e975f5cSPL ID 61378ee8-cc2f-4f55-954b-4eb55e975f5cSPL set ID be514be6-727a-4d6c-993b-52144f8e6de8RxCUI 904955UNII J12U072QL0
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N462756021840 followed by a unit qualifier and the quantity

Package 62756-0218-40. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 3, 2026.

Indications (excerpt from the label)

Ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women. ( 1.1 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.2 ) 1.1 Treatment of Postmenopausal Osteoporosis Ibandronate sodium injection is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, ibandronate sodium injection increases bone mineral density (BMD) and reduces the incidence of vertebral fractures [see Clinical Studies ( 14 )] . 1.2 Important Limitations of Use The safety and effectiveness of ib…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 62756-218

What is NDC 62756-218?: 62756-218 is the product NDC for Ibandronate Sodium, Ibandronate sodium 3 mg/3mL injection, solution, listed with the FDA by Sun Pharmaceutical Industries, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Ibandronate Sodium.
What is the active ingredient?: Ibandronate sodium.
Who is the labeler?: Sun Pharmaceutical Industries, Inc., NDC labeler code 62756. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Ibandronate Sodium?: 7 other product NDCs are listed under this name. See all Ibandronate Sodium NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Ibandronate Sodium NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Ibandronate Sodium	Ibandronate sodium 150 mg/1	TabletOral	Bionpharma Inc.	69452-378	69452-0378-74
Ibandronate Sodium	Ibandronate sodium 150 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-150	33342-0150-5233342-0150-53
Ibandronate Sodium	Ibandronate sodium 3 mg/3mL	InjectionIntravenous	Apotex Corp.	60505-6097	60505-6097-00
Ibandronate Sodium	Ibandronate sodium 3 mg/3mL	Injection, SolutionIntravenous	Eugia US LLC	55150-191	55150-0191-83
Ibandronate sodium	Ibandronate sodium 150 mg/1	TabletOral	A-S Medication Solutions	50090-7654	50090-7654-00
Ibandronate sodium	Ibandronate sodium 150 mg/1	TabletOral	Dr. Reddy's Laboratories Limited	55111-575	55111-0575-0355111-0575-43
Ibandronate Sodium	Ibandronate sodium 150 mg/1	Tablet, Film coatedOral	Golden State Medical Supply, Inc.	60429-643	60429-0643-73